Under construction – not a live service
Sign in
Enrolling by invitationPhase 3

Long-term study of ACP-204 for psychosis linked to Alzheimer's disease

Checks the long-term safety of ACP-204 in older adults with Alzheimer's psychosis.

Plain-language title generated from the registry record
Registry title: ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Key facts

Where
Abington, Aventura, Costa Mesa, Cypress, Doral, Fresno, Garden Grove, Hialeah, Houston, Miami, Miami Gardens, Miami Lakes, and Scottsdale, United StatesSee the 23 sites
Phase
Phase 3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 55 and 95 years old?

Source: NCT06194799, who can take part

Where in United States

  • Abington Neurological AssociatesAbington, United StatesNo longer taking part
  • Humanity Clinical Research, CorpAventura, United StatesNo longer taking part
  • ATP Clinical ResearchCosta Mesa, United StatesNo longer taking part
  • Horizon Clinical Research GroupCypress, United StatesNo longer taking part
  • First Excellent ResearchDoral, United StatesNo longer taking part
  • Neuro-Pain Medical CenterFresno, United StatesNo longer taking part
  • National Institute Of Clinical ResearchGarden Grove, United StatesNo longer taking part
  • New Life Medical Research CenterHialeah, United StatesNo longer taking part
  • Reliable Clinical Research LLCHialeah, United StatesNo longer taking part
  • Clinical Trial Network LLCHouston, United StatesNo longer taking part
  • Kaleidoscope Clinical ResearchHouston, United StatesNo longer taking part
  • Uni Texas Health Science CenterHouston, United StatesNo longer taking part
  • ABBA Medical Research LLCMiami, United StatesNo longer taking part
  • Advanced Clinical ResearchMiami, United StatesNo longer taking part
  • Future Care Solution LLCMiami, United StatesNo longer taking part
  • Homestead Associates in Research Inc.Miami, United StatesNo longer taking part
  • MediClear Medical & Research Center, Inc.Miami, United StatesNo longer taking part
  • Premier Clinical Research Institute IncMiami, United StatesNo longer taking part
  • Quantum Clinical TrialsMiami, United StatesNo longer taking part
  • Verus Clinical ResearchMiami, United StatesNo longer taking part
  • New Med ResearchMiami Gardens, United StatesNo longer taking part
  • Floridian Neuroscience InstituteMiami Lakes, United StatesNo longer taking part
  • Clinical Endpoints, LLCScottsdale, United StatesNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
ACADIA Pharmaceuticals Inc.
Trial code
NCT06194799EU 2023-507351-29-00
Record updated
4 November 2026
Original description
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.Read full original descriptionShow less

A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis

This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.

Inclusion: Subject has successfully completed ACP-204-006 study; Male or female (age 55 to 95 years old): female must be of non-childbearing potential, male must take appropriate contraceptive method if partner has childbearing potential; Subject has a designated study partner/caregiver; Subjects are able to complete all study visits with a study partner/caregiver; Signed inform consent form with a caregiver or legal representative.

Exclusion: Requires treatment with a medication prohibited by the protocol; Is in hospice and receiving end-of-life palliative care, or has become bedridden; Unstable clinically significant medical condition other than AD; Any medical condition that in the opinion of the investigator may affect safety or ability to complete the study; Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.

ClinicalTrials.gov NCT06194799 · EU CTIS 2023-507351-29-00